Noninvasive Imaging Approach to Quantifying NASH and Assessing Emerging Therapeutics


Nonalcoholic fatty liver disease (NAFLD) affects nearly 25% of the population – and of those, around 25% progress to nonalcoholic steatohepatitis (NASH). Still, there remains no FDA-approved treatment for NASH.

This webinar explores a noninvasive approach to better understand NASH disease pathology for earlier diagnosis and new therapeutic development, and discusses emerging therapeutics now in clinical trials.